Pseudomonas aeruginosa

20,423views

Pseudomonas aeruginosa

COMP 4

COMP 4

Staphylococcus epidermidis
Staphylococcus aureus
Staphylococcus saprophyticus
Streptococcus viridans
Streptococcus pneumoniae
Streptococcus pyogenes (Group A Strep)
Streptococcus agalactiae (Group B Strep)
Listeria monocytogenes
Corynebacterium diphtheriae (Diphtheria)
Nocardia
Actinomyces israelii
Pseudomonas aeruginosa
Klebsiella pneumoniae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Yersinia pestis (Plague)
Neisseria meningitidis
Neisseria gonorrhoeae
Moraxella catarrhalis
Francisella tularensis (Tularemia)
Bordetella pertussis (Whooping cough)
Haemophilus influenzae
Mycobacterium tuberculosis (Tuberculosis)
Mycoplasma pneumoniae
Chlamydia pneumoniae
Chlamydia trachomatis
Borrelia burgdorferi (Lyme disease)
Coxiella burnetii (Q fever)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Viral structure and functions
Herpes simplex virus
Adenovirus
Parvovirus B19
Coxsackievirus
Poliovirus
Rhinovirus
Hepatitis A and Hepatitis E virus
Influenza virus
Respiratory syncytial virus
Human parainfluenza viruses
Rubella virus
Acute respiratory distress syndrome
Emphysema
Asthma
Bronchiectasis
Chronic bronchitis
Cystic fibrosis
Alpha 1-antitrypsin deficiency
Restrictive lung diseases
Idiopathic pulmonary fibrosis
Pneumonia
Obstructive lung diseases: Pathology review
Tuberculosis: Pathology review
Pneumonia: Pathology review
Restrictive lung diseases: Pathology review
Lung volumes and capacities
Pressure-volume loops
Changes in pressure-volume loops
Acute respiratory distress syndrome: Clinical
Respiratory distress syndrome: Pathology review
Upper respiratory tract infection
Bacterial epiglottitis
Bacillus anthracis (Anthrax)
Vaccinations
Yellow fever virus
Vaccinations: Clinical
Renal tubular acidosis
Minimal change disease
Diabetic nephropathy
Focal segmental glomerulosclerosis (NORD)
Amyloidosis
Lupus nephritis
Membranous nephropathy
Membranoproliferative glomerulonephritis
Poststreptococcal glomerulonephritis
IgA nephropathy (NORD)
Rapidly progressive glomerulonephritis
Alport syndrome
Kidney stones
Hydronephrosis
Acute pyelonephritis
Chronic pyelonephritis
Renal azotemia
Prerenal azotemia
Postrenal azotemia
Renal cortical necrosis
Renal papillary necrosis
Chronic kidney disease
Medullary sponge kidney
Medullary cystic kidney disease
Renal cell carcinoma
Nephroblastoma (Wilms tumor)
Beckwith-Wiedemann syndrome
Angiomyolipoma
WAGR syndrome
Posterior urethral valves
Hypospadias and epispadias
Vesicoureteral reflux
Bladder exstrophy
Urinary incontinence
Neurogenic bladder
Lower urinary tract infection
Transitional cell carcinoma
Non-urothelial bladder cancers
Renal failure: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Urinary tract infections: Pathology review
Urinary incontinence: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Blastomycosis
Histoplasmosis
Mucormycosis
Aspergillus fumigatus
Cryptococcus neoformans
Candida
Schistosomes
Croup
Enterococcus
Clostridium difficile (Pseudomembranous colitis)
Bacillus cereus (Food poisoning)
Escherichia coli
Proteus mirabilis
Vibrio cholerae (Cholera)
Brucella
Cytomegalovirus
Poxvirus (Smallpox and Molluscum contagiosum)
Mumps virus
Measles virus
Dengue virus
Ebola virus
Hantavirus
Coccidioidomycosis and paracoccidioidomycosis
Pneumocystis jirovecii (Pneumocystis pneumonia)
Cryptosporidium
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Azoles
Antihistamines for allergies
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Sleep apnea
Pulmonary edema
Mesothelioma
Superior vena cava syndrome
Lung cancer
Pancoast tumor
Laryngitis
Sinusitis
Retropharyngeal and peritonsillar abscesses
Allergic rhinitis
Benign prostatic hyperplasia
Prostate cancer
Potter sequence
Prostate disorders and cancer: Pathology review
Testicular and scrotal conditions: Pathology review

Transcript

Watch video only

Content Reviewers

Pseudomonas aeruginosa, or P. aeruginosa, is a gram-negative bacterium that is abundant in the environment.

It tends to opportunistically infect high-risk individuals, and is well known for its multi-drug resistance, making it hard to treat.

P. aeruginosa is an encapsulated, gram-negative, rod bacterium, that’s an obligate aerobe, so it uses oxygen for metabolism through cellular respiration.

It does not ferment lactose and does not make spores; but it’s catalase, citrate, and oxidase positive.

It has a flagellum, kind of like a tail, at one end for motility; and has multiple hair-like appendages, called pili, all over that help with adhesion to other cells.

It also has a number of multidrug efflux pumps that efficiently pump medications out of the bacteria making it resistant to a variety of antibiotics.

In addition it’s able to make beta-lactamases that degrade beta-lactam antibiotics as well as aminoglycoside-modifying enzymes that alter aminoglycoside antibiotics - rendering them ineffective. In short, it’s defenses are strong.

P. aeruginosa is everywhere in the environment - in soil; in the home, and in hospitals - where it’s found on improperly cleaned medical equipment and devices, various surfaces, and on the hands of health care workers.

It can survive for months on dry surfaces and inanimate objects – but particularly loves humid or wet conditions; like hot tubs, contact lens cases, catheters, and medical ventilators.

Transmission can occur when broken skin or mucous membranes come in contact with contaminated surfaces; or when aerosols containing P. aeruginosa are inhaled after an infected person coughs or sneezes.

Now, a P. aeruginosa infection is actually not too common in the general population.

It’s an opportunistic bacterium, meaning that it frequently causes infections in high-risk individuals like those with cystic fibrosis, chronic granulomatous disease, and type 2 diabetes mellitus.

It’s also common among individuals with an immunodeficiency; IV drug abusers, or those with severe burns or deep wounds.

P. aeruginosa produces several virulence factors to help it invade epithelial cells and survive an attack from the immune system.

First, there’s endotoxin, a molecule that’s made up of a lipid and polysaccharide.

The endotoxin sits on the outer membrane of the bacteria, and it’s recognized by the immune system as being foreign and causes a really strong immune reaction that can cause extensive damage to the host cells.

Certain strains of P. aeruginosa also produce a mucoid exopolysaccharide capsule, and this contributes to the formation of a biofilm - a slimy, sticky, gummy material – that surrounds colonies of P. aeruginosa and acts like a shield to protect the bacteria from immune cells as well as antibiotics.

P. aeruginosa can also produce toxins that can be injected directly into the host epithelial cells through a type III secretion system.

It’s kind of like a fine needle that pierces the host cell and forms a tunnel between the P. aeruginosa and the host epithelial cell, allowing toxins to pass through.

P. aeruginosa also releases toxins into the extracellular environment.

For example, it releases phospholipase C which is an enzyme that degrades the host cell membrane causing the cell to lyse.

Other secreted toxins have to move within the cell to act.

For example, exotoxin A is released by P. aeruginosa into the extracellular environment and then taken up by nearby host cells where it targets ADP-ribosylation of elongation factor 2, which is a ribosomal protein.

Key Takeaways

Pseudomonas aeruginosa is an aerobic, gram-negative, rod-shaped bacterium commonly found in the environment, such as in soil, in the home, and in hospitals. It is known to opportunistically infect immunocompromised people, and for its multi-drug resistance that is hard to treat.

It is also known to form biofilms that provide it with extra protection against antibiotics on top of its preexisting multi-drug resistance. P. aeruginosa can cause a variety of infections, including urinary tract infections, wound infections, sepsis, and lung infections in people with cystic fibrosis. Treatment for P. aeruginosa infections is with antibiotics, such as aminoglycosides, carbapenems, and cephalosporins.